1. GRAIL to present at Jefferies Global Healthcare Conference on June 4. 2. The conference will highlight GRAIL's early cancer detection capabilities. 3. GRAIL's technology focuses on multiple cancer types and precision oncology.
The conference presentation can enhance investor confidence and visibility for GRAIL, similar to past healthcare events that propelled biotech stock prices due to favorable projections or updates.
The conference aligns with GRAIL's mission and advancements, thus generating potential investor interest.
The event is upcoming and generally leads to immediate market reactions based on investor sentiment during and after the conference.
MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for replay for at least 30 days after the event.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment, and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. For more information, visit grail.com.
SOURCE GRAIL, Inc.